Real-World check: can this drug help patients avoid surgery for rectal cancer?
NCT ID NCT07269249
Summary
This study aims to see how well the immunotherapy drug dostarlimab works for patients with a specific type of locally advanced rectal cancer in real-world medical practice, not just in a controlled trial. It will follow 50 patients in Italy who are already receiving this treatment to measure how their tumors respond and monitor for side effects. The goal is to understand if the drug can effectively shrink tumors and potentially help patients avoid major surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CANCER (LARC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ASL Napoli 1, Presidio Ospedaliero Ospedale del mare, Oncologia medica
NOT_YET_RECRUITINGNapoli, 80131, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
IRCCS Fondazione G. Pascale, Unità Operativa Complessa Oncologia Addominale
RECRUITINGNapoli, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.